Soo-Young Lee

Soo-Young Lee

Auto-generated profile, based on publicly available information

Soo-Young Lee

Celltrion Inc

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Science
Verified
Journal Article
Open access
KHKathryn M. Hastie
Kathryn M. Hastie
HLHaoyang Li
Haoyang Li
DBDaniel Bedinger
Daniel Bedinger
SSSharon L. Schendel
Sharon L. Schendel
SDS. Moses Dennison
S. Moses Dennison
ESErica Ollmann Saphire
Erica Ollmann Saphire
Community of antibodies against COVID-19: The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection. The Coronavirus Immunotherapeutic Consortium (CoVIC), comprising 56 partners across the world, has analyzed a panel of 269 monoclonal antibodies (mAbs) and, on the basis of competition profiles, sorted 186 mAbs that target the receptor binding domain into seven communities. Hastie et al . went on to structurally analyze representative antibody binding and used pseudovirus neutralization assays to study the effect of spike mutations on antibody function, including the combinations of mutations found in certain variants of concern. These results are important to guide both treatment and prevention efforts. —VV

12 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKCheolmin Kim
Cheolmin Kim
DRDong-Kyun Ryu
Dong-Kyun Ryu
JLJihun Lee
Jihun Lee
YKYoung-Il Kim
Young-Il Kim
JSJi-Min Seo
Ji-Min Seo
SLSoo-Young Lee
Soo-Young Lee
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19.

13 September 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DRDong-Kyun Ryu
Dong-Kyun Ryu
BKBobin Kang
Bobin Kang
HNHanmi Noh
Hanmi Noh
SWSun-Je Woo
Sun-Je Woo
MLMin-Ho Lee
Min-Ho Lee
SLSoo-Young Lee
Soo-Young Lee

1 August 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DRDong-Kyun Ryu
Dong-Kyun Ryu
RSRina Song
Rina Song
MKMinsoo Kim
Minsoo Kim
YKYoung-Il Kim
Young-Il Kim
CKCheolmin Kim
Cheolmin Kim
SLSoo-Young Lee
Soo-Young Lee

29 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KYKye Sook Yi
Kye Sook Yi
JCJung-Ah Choi
Jung-Ah Choi
PKPankyeom Kim
Pankyeom Kim
DRDong-Kyun Ryu
Dong-Kyun Ryu
EYEunji Yang
Eunji Yang
MSManki Song
Manki Song
There are several broadly neutralizing monoclonal antibodies that neutralize influenza viruses with different mechanisms from traditional polyclonal antibodies induced by vaccination. CT149, which is one of the broadly neutralizing antibodies, was also previously reported to neutralize group 2 and some of group 1 influenza viruses (13 out of 13 tested group 2 viruses and 5 out of 11 group 1 viruses). In this study, we developed another antibody with the aim of compensating partial coverage of CT149 against group 1 influenza viruses. CT120 was screened among different antibody candidates and mixed with CT149. Importantly, although the binding sites of CT120 and CT149 are close to each other, the two antibodies do not interfere. The mixture of CT120 and CT149, which we named as CT-P27, showed broad efficacy by neutralizing 37 viruses from 11 different subtypes, of both group 1 and 2 influenza A viruses. Moreover, CT-P27 showed in vivo therapeutic efficacy, long prophylactic potency, and synergistic effect with oseltamivir in influenza virus-challenged mouse models. Our findings provide a novel therapeutic opportunity for more efficient treatment of influenza.

27 September 2022 in Emerging Microbes & Infections
Verified
Journal Article
Open access
JSJi-Min Seo
Ji-Min Seo
BKBobin Kang
Bobin Kang
RSRina Song
Rina Song
HNHanmi Noh
Hanmi Noh
CKCheolmin Kim
Cheolmin Kim
SLSoo-Young Lee
Soo-Young Lee
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant morbidity and mortality worldwide. Despite a successful vaccination programme, the emergence of mutated variants that can escape current levels of immunity mean infections continue. Herein, we report the development of CT-P63, a broad-spectrum neutralizing monoclonal antibody. In vitro studies demonstrated potent neutralizing activity against the most prevalent variants, including Delta and the BA.1 and BA.2 sub-lineages of Omicron. In a transgenic mouse model, prophylactic CT-P63 significantly reduced wild-type viral titres in the respiratory tract and CT-P63 treatment proved efficacious against infection with Beta, Delta, and Omicron variants of SARS-CoV-2 with no detectable infectious virus in the lungs of treated animals. A randomized, double-blind, parallel-group, placebo-controlled, Phase I, single ascending dose study in healthy volunteers (NCT05017168) confirmed the safety, tolerability, and pharmacokinetics of CT-P63. Twenty-four participants were randomized and received the planned dose of CT-P63 or placebo. The safety and tolerability of CT-P63 were evaluated as primary objectives. Eight participants (33.3%) experienced a treatment-emergent adverse event (TEAE), including one grade ≥3 (blood creatine phosphokinase increased). There were no deaths, treatment-emergent serious adverse events, TEAEs of special interest, or TEAEs leading to study drug discontinuation in the CT-P63 groups. Serum CT-P63 concentrations rapidly peaked before declining in a biphasic manner and systemic exposure was dose proportional. Overall, CT-P63 was clinically safe and showed broad-spectrum neutralizing activity against SARS-CoV-2 variants in vitro and in vivo.